Interleukin 10 reduces mortality from severe peritonitis in mice.
Interleukin 10 (IL-10) is known to suppress the induction of proinflammatory cytokines such as tumor necrosis factor (TNF) and IL-1 and is itself induced by monocytes and macrophages during sepsis. We studied the therapeutic efficacy of IL-10 by testing its effect on the survival rate in the murine cecal ligation-and-puncture (CLP) model. Administration of 1 microgram or more of recombinant murine IL-10 6 h after induction of sepsis decreased lethality in septic mice significantly and also suppressed the elevation of circulating TNF after sepsis. However, treatment with the same dose of IL-10 simultaneously or 6 h before induction of CLP had no effect on survival, and treatment with anti-TNF antibody after induction of CLP had no effect on the survival rate. These data suggest that cytokine modulation with IL-10 is a potential candidate for the treatment of sepsis and sepsis-related multiple organ failure.
Kato
T
T
Department of Surgery II, Osaka University Medical School, Japan.
Murata
A
A
Ishida
H
H
Toda
H
H
Tanaka
N
N
Hayashida
H
H
Monden
M
M
Matsuura
N
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D016753:Interleukin-10 / Q000097:blood / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D010538:Peritonitis / Q000150:complications / Q000401:mortality / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000150:complications / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10